2025-02-01 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Analysis Report

**0) Key Figures & Initial Analysis:**

VRTX, Vertex Pharmaceuticals Inc., is a biotechnology company focused on the discovery, development, and commercialization of innovative medicines for serious diseases.

The cumulative return of VRTX significantly outperforms the S&P 500 (VOO) over the observed period.  While VRTX shows a cumulative return of 162.38%, VOO shows only 119.91%, resulting in a difference of 42.5%.  This places the relative divergence at the 67.9th percentile of its historical range (max: 93.5, min: -65.6). This suggests strong outperformance relative to the broader market, although it's important to remember this is a snapshot in time and past performance doesn't guarantee future results.


**1) Alpha & Beta Analysis:**

The provided data shows VRTX exhibiting high CAGR (Compound Annual Growth Rate) over several periods, indicating strong historical growth. However, the MDD (Maximum Drawdown) also fluctuates significantly, highlighting periods of substantial risk.  The Alpha values suggest consistent outperformance against the market benchmark, particularly in 2017-2019 and 2021-2023. The Beta values generally hover around 0.5, indicating lower volatility than the overall market (Beta of 1). The market capitalization (Cap(B)) shows steady growth over the years, reflecting the company's success.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 48.0% | 21.7% | 19.0% | 0.1 | 38.6 |
| 2016-2018  | 66.0% | 11.0% | 47.0% | 0.1 | 42.7 |
| 2017-2019  | 88.0% | 11.0% | 57.0% | 0.6 | 56.4 |
| 2018-2020  | 17.0% | 22.8% | -10.0% | 0.2 | 60.9 |
| 2019-2021  | -9.0% | 22.8% | -80.0% | 0.2 | 56.5 |
| 2020-2022  | 10.0% | 22.8% | 2.0% | 0.2 | 74.4 |
| 2021-2023  | 84.0% | 9.6% | 60.0% | 0.5 | 104.8 |
| 2022-2024  | 64.0% | 13.7% | 31.0% | 0.5 | 103.7 |
| 2023-2025  | 54.0% | 13.7% | -7.0% | 0.5 | 118.9 |


**2) Recent Price Movement:**

* **Closing Price:** $461.68
* **5-day Moving Average:** $445.23
* **20-day Moving Average:** $424.75
* **60-day Moving Average:** $446.79

The price is above all three moving averages, suggesting a potential upward trend.  The recent change of $5.31 from the previous close indicates a significant daily increase.


**3) Technical Indicators & Expected Return:**

* **RSI (Relative Strength Index):** 81.4  –  Indicates overbought conditions, suggesting a potential correction.
* **PPO (Percentage Price Oscillator):** 1.19 –  Positive value confirms an uptrend.
* **Delta_Previous_Relative_Divergence:** +9.3 – Shows a short-term upward trend.
* **Expected Return (2+ years):** 18.7% –  This represents a significant outperformance compared to the S&P 500 over the long term.  The substantial daily price increase mentioned above reflects significant recent market activity.


**4) Recent Earnings Analysis:**

The earnings data shows significant volatility.  There are instances of high EPS alongside lower ones, suggesting some degree of inconsistency or perhaps cyclical factors within their business model.  Revenue remains relatively stable, demonstrating overall growth. Further investigation into the reasons behind the EPS fluctuations is needed.


| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2024-11-05 | 4.05  | $2.77B     |
| 2024-08-02 | -13.92 | $2.65B     |
| 2024-05-07 | 4.26  | $2.69B     |
| 2023-11-07 | 4.01  | $2.48B     |
| 2024-11-05 | 4.01  | $2.48B     |


**5) Financial Information:**

Revenue remains consistently high, indicating strong sales performance.  Profit margins are generally excellent, exceeding 85%.  However, the ROE (Return on Equity) displays some volatility, with both very positive and highly negative values, warranting closer analysis to understand the underlying factors.


Revenue and Profitability:

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-09-30 | $2.77B | 85.84% |
| 2024-06-30 | $2.65B | 85.94% |
| 2024-03-31 | $2.69B | 87.27% |
| 2023-12-31 | $2.52B | 85.38% |
| 2023-09-30 | $2.48B | 87.17% |

Capital and Profitability:

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-09-30 | $15.63B | 6.69% |
| 2024-06-30 | $14.77B | -24.32% |
| 2024-03-31 | $18.55B | 5.93% |
| 2023-12-31 | $17.58B | 5.51% |
| 2023-09-30 | $16.51B | 6.27% |


**6) Overall Conclusion:**

VRTX exhibits a strong track record of growth and market outperformance.  However, considerable volatility exists in both its earnings and ROE, requiring deeper investigation into the underlying drivers.  While the current price is above key moving averages and the expected long-term return is positive, the overbought RSI suggests caution.  Further due diligence, including a thorough analysis of the company's financials and future prospects, is crucial before making any investment decisions.  The high Alpha and consistent revenue growth are encouraging, but the significant fluctuations in EPS and ROE demand careful consideration of risk.
